PROKMEDIUM SIGNALREGULATORY10-K

ProKidney completed a corporate domestication from the Cayman Islands to Delaware on July 1, 2025, while burning through significant cash reserves despite reducing R&D spending.

The redomestication to Delaware provides more familiar corporate governance for U.S. investors and may signal management's commitment to operating as a U.S.-focused entity. However, the company's financial position shows continued cash burn with assets declining nearly 24%, raising questions about runway for this clinical-stage biotechnology company.

Comparing 2026-03-18 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

ProKidney's financial position deteriorated with total assets falling 23.9% to $335.6M and current assets declining 29.1% to $280.7M, indicating significant cash burn during the period. While the company reduced R&D expenses by 10.6% to $114.1M and cut capital expenditures in half to $15.2M, net losses still increased 12.7% to $69.0M, demonstrating ongoing operational challenges. The substantial decline in cash resources combined with continued losses suggests potential liquidity concerns for this clinical-stage company.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-55.6%
$9K→$4K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
-48.5%
$29.5M→$15.2M

Capex reduced 48.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-29.1%
$395.9M→$280.7M

Current assets declined 29.1% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-23.9%
$441.1M→$335.6M

Total assets contracted 23.9% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-15.1%
$36.2M→$30.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Net Income
P&L
-12.7%
-$61.2M→-$69.0M

Net income declined 12.7% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
-11.8%
$39.4M→$34.8M

Liabilities reduced 11.8% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-10.6%
$127.7M→$114.1M

R&D spending cut 10.6% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+10.2%
-$183.7M→-$165.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-17
ADDED
(Exact name of Registrant as specified in its Charter) Delaware 98-1586514 (State or other jurisdiction of incorporation or organization) (I.R.S.
As of March 17, 2026, there were 141,942,905 shares of Class A common stock, par value $0.0001 per share and 159,973,180 shares of Class B common stock, par value $0.0001 per share, outstanding.
Exhibits and Financial Statement Schedules 96 Item 16 Form 10-K Summary 98 i Effective July 1, 2025 (the Domestication Date ), the Company completed a domestication process through which it changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware (the Domestication ).
ProKidney Corp., the Cayman Islands exempted company ( ProKidney Cayman ) deregistered as an exempted company in the Cayman Islands pursuant to Sections 206 and 207 of the Companies Act (as amended) of the Cayman Islands (the Companies Act ), and domesticated and continued its existence as a corporation incorporated in the State of Delaware ( ProKidney Delaware ) pursuant to Section 388 of the General Corporation Law of the State of Delaware (the DGCL ), effective as of the Domestication Date.
In this Annual Report on Form 10-K, the terms we , us , our , the Company and ProKidney (i) for periods prior to the Domestication Date, refer to ProKidney Cayman and its consolidated subsidiaries and (ii) for periods at or after the Domestication Date, refer to ProKidney Delaware and its consolidated subsidiaries.
Similarly, throughout this Annual report, unless otherwise noted, references to common stock refer to ordinary shares before the Domestication and common stock subsequent to the Domestication.
For a description of our equity securities following the Domestication, refer to the Description of the Registrant s Capital Stock filed as Exhibit 4.1 hereto.
Overview We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease ( CKD ) and diabetes.
Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function.
Our lead product candidate, rilparencel, is the only cell therapy in Phase 3 clinical study for the treatment of advanced CKD and type 2 diabetes.
REMOVED
(Exact name of Registrant as specified in its Charter) Cayman Islands 98-1586514 (State or other jurisdiction of incorporation or organization) (I.R.S.
As of March 17, 2025, there were 129,536,121 Class A ordinary shares, par value $0.0001 per share and 163,161,528 Class B ordinary shares, par value $0.0001 per share, outstanding.
Exhibits and Financial Statement Schedules 118 Item 16 Form 10-K Summary 120 i In this Annual Report on Form 10-K, the terms we , us , our , the Company and ProKidney mean ProKidney Corp.
On July 11, 2022 (the Closing Date ), Social Capital Suvretta Holdings Corp.
III, an exempted company registered under the laws of the Cayman Islands ( SCS and after the Business Combination described herein, the Company ), consummated a business combination (the Business Combination ) pursuant to the terms of the Business Combination Agreement, dated as of January 18, 2022 (the Business Combination Agreement ), by and between SCS and ProKidney LP, a limited partnership organized under the laws of Ireland ( PKLP ).
Pursuant to the Business Combination and the other transactions contemplated by the Business Combination Agreement (collectively, the Transactions , and such completion, the Closing ), PKLP became a subsidiary of SCS, and SCS changed its name to ProKidney Corp.
Overview Prior to July 11, 2022, we were a blank check company registered under the laws of the Cayman Islands and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
On July 11, 2022, we completed the Business Combination pursuant to the Business Combination Agreement, that we entered into with PKLP.
Upon the completion of the Business Combination, we changed our name to ProKidney Corp.
We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform that has the potential to treat multiple chronic kidney diseases using cells isolated from the patient intended for treatment.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →